Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 319 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PF Clear all
Terminated Phase 1 Interventional Results available

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

NCT04543188
View directory record Official record
Conditions
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms, Malignant Neoplasms
Interventions
PF-07284890, Binimetinib, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
39
States / cities
Duarte, California • San Francisco, California • Orlando, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 1Phase 2 Interventional Results available

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

NCT03318900
View directory record Official record
Conditions
COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive, Recurrent Ovarian Carcinoma
Interventions
Aldesleukin, CD8-Positive T-Lymphocyte, Cyclophosphamide, Leukapheresis, Utomilumab
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Digital Device Users Who Are Treated With Systane Hydration PF

NCT04837807
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Hydration PF
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 2 Interventional Results available

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

NCT01891344
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Oral rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
36
States / cities
Anchorage, Alaska • Tucson, Arizona • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Nov 4, 2026, 9:03 AM EST
Active, not recruiting Phase 1 Interventional Results available

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

NCT02142803
View directory record Official record
Conditions
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Charlestown, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 4, 2026, 9:03 AM EST
Recruiting Phase 4 Interventional

The Effectiveness of Systane PRO Preservative Free Verses Blink Triple Care Preservative Free

NCT07745062
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Systane PRO, Blink tears
Drug
Lead sponsor
Gordon Schanzlin New Vision
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 1 Interventional

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

NCT03665454
View directory record Official record
Conditions
Parkinson Disease
Interventions
PF-06412562, Standard of Care Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 1 Interventional Results available

A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors

NCT01105533
View directory record Official record
Conditions
Neoplasm
Interventions
PF-00337210
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Detroit, Michigan • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 2 Interventional Results available

1% Chloroprocaine(PF) vs. Bupivacaine Spinals

NCT03324984
View directory record Official record
Conditions
Return of Motor and Sensory Blockade, Anesthesia, Spinal, Decrease Discharge Time Status Post Hemorrhoidectomy
Interventions
1% chloroprocaine, 0.75% bupivacaine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532

NCT01388829
View directory record Official record
Conditions
Healthy
Interventions
Treatment A, Treatment B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 10, 2011 · Synced Nov 4, 2026, 9:03 AM EST
Terminated Phase 2 Interventional Results available

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

NCT04171700
View directory record Official record
Conditions
Solid Tumor
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.

NCT00959803
View directory record Official record
Conditions
Healthy
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2009 · Synced Nov 4, 2026, 9:03 AM EST
Active, not recruiting Phase 1 Interventional

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

NCT01829568
View directory record Official record
Conditions
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
Interventions
Ibrutinib, Lenalidomide, Rituximab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

NCT04909853
View directory record Official record
Conditions
Renal Impairment
Interventions
PF-07321332/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Nov 4, 2026, 9:03 AM EST
Terminated Phase 1 Interventional Results available

PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine

NCT00437203
View directory record Official record
Conditions
Neoplasms
Interventions
PF-00477736, gemcitabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Santa Monica, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

NCT04756531
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07321332 Dose 1, PF-07321332 Dose 2, PF-07321332 Dose 3, PF-07321332 Dose 4, PF-07321332 Dose 5, PF-07321332 Dose 4 or Placebo (Fed)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Nov 4, 2026, 9:03 AM EST
Completed Not applicable Interventional

Heterogeneity in ASD: Biological Mechanisms, Trajectories, and Treatment Response

NCT03253081
View directory record Official record
Conditions
Children With Autism
Interventions
PARENT focused intervention, CHILD focused intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Months to 36 Months
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 2Phase 3 Interventional

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

NCT07354516
View directory record Official record
Conditions
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Interventions
QLS-111-FDC, Latanoprost (0.005%)
Combination Product · Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

NCT03662516
View directory record Official record
Conditions
Healthy Females
Interventions
PF-04965842, Ethinyl estradiol (EE) and levonorgestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Nov 4, 2026, 9:03 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Improving Women's Health by Using an Electronic Pelvic Floor Questionnaire

NCT00880880
View directory record Official record
Conditions
Urinary Incontinence, Fecal Incontinence, Pelvic Floor Disorders
Interventions
e-PAQ-PF
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years and older · Female only
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Nov 4, 2026, 9:03 AM EST
Recruiting Not applicable Interventional

Practice Facilitation to Enhance Implementation of a Pediatric Suicide Prevention Pathway

NCT06619782
View directory record Official record
Conditions
Suicide Prevention
Interventions
Practice Facilitation, Training in National Institute of Mental Health Youth Suicide Prevention Pathway
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 80 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Nov 4, 2026, 9:03 AM EST
Recruiting Not applicable Interventional

Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease

NCT06919224
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
mHealth app + booklets
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Chicago, Illinois • St Louis, Missouri • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 4, 2026, 9:03 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Glasdegib for Chronic Graft-Versus-Host Disease

NCT04111497
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Fasciitis
Interventions
Glasdegib
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Nov 4, 2026, 9:03 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

NCT03599063
View directory record Official record
Conditions
Healthy
Interventions
PF-06946860, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Nov 4, 2026, 9:03 AM EST